Lidbree (Lidocaine)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium that initiates an action potential. This interruption stops nerve signal transmission, producing a reversible loss of sensation in the area where the drug is applied.

The specific dose and concentration of Lidbree are determined by the treating physician based on the type of intrauterine procedure, patient characteristics, and clinical guidelines. Healthcare providers set the appropriate volume and strength at the point of care.

Safety data for intrauterine lidocaine use in pregnancy are limited. It should only be used when the anticipated benefit to the mother outweighs any potential risk to the fetus. Lidocaine is excreted in breast milk in small amounts; caution is advised, and a prescriber should evaluate the risk‑benefit ratio.

To request Lidbree, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidbree’s active ingredient, lidocaine, is a short‑acting amide local anesthetic offering rapid onset and predictable duration. Compared with longer‑acting agents such as bupivacaine, lidocaine provides quicker recovery of sensation, which can be advantageous for short procedures. However, the choice depends on procedural length, required depth of anesthesia, and individual patient factors.

Lidbree should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures or direct sunlight.

Lidbree is administered intrauterinely by a qualified healthcare professional. The drug is typically instilled or injected directly into the uterine cavity using a sterile catheter or syringe, following aseptic technique and the prescriber’s dosage instructions.

The most serious adverse events include severe allergic reactions (anaphylaxis), systemic lidocaine toxicity leading to central nervous system symptoms such as seizures, and cardiac arrhythmias or conduction disturbances. Immediate medical attention is required if any of these signs appear.

Lidbree should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, and individuals receiving concurrent high‑dose local anesthetics that could cause cumulative toxicity. Clinical judgment is essential for all contraindications.